首页|期刊导航|癌症生物学与医学（英文版）|Plasma L-aspartic acid predicts the risk of gastric cancer and modifies the primary prevention effect:a multistage metabolomic profiling and Mendelian randomization study

Plasma L-aspartic acid predicts the risk of gastric cancer and modifies the primary prevention effect:a multistage metabolomic profiling and Mendelian randomization study

Mengyuan Wang Kaifeng Pan Wenqing Li Zhouyi Yin Hengmin Xu Zongchao Liu Sha Huang Wenhui Wu Yang Zhang Tong Zhou Weicheng You

癌症生物学与医学（英文版）2025，Vol.22Issue(5)：525-538,14.

癌症生物学与医学（英文版）2025，Vol.22Issue(5)：525-538,14.DOI:10.20892/j.issn.2095-3941.2024.0523

Plasma L-aspartic acid predicts the risk of gastric cancer and modifies the primary prevention effect:a multistage metabolomic profiling and Mendelian randomization study

Mengyuan Wang ¹Kaifeng Pan ¹Wenqing Li ¹Zhouyi Yin ¹Hengmin Xu ¹Zongchao Liu ¹Sha Huang ¹Wenhui Wu ¹Yang Zhang ²Tong Zhou ²Weicheng You²

作者信息

1. State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers,Department of Cancer Epidemiology,Peking University Cancer Hospital&Institute,Beijing 100142,China
2. Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Cancer Epidemiology,Peking University Cancer Hospital&Institute,Beijing 100142,China
折叠

摘要

关键词

Gastric cancer/plasma metabolites/Mendelian randomization/L-aspartic acid

Key words

Gastric cancer/plasma metabolites/Mendelian randomization/L-aspartic acid

引用本文复制引用

Mengyuan Wang,Kaifeng Pan,Wenqing Li,Zhouyi Yin,Hengmin Xu,Zongchao Liu,Sha Huang,Wenhui Wu,Yang Zhang,Tong Zhou,Weicheng You..Plasma L-aspartic acid predicts the risk of gastric cancer and modifies the primary prevention effect:a multistage metabolomic profiling and Mendelian randomization study[J].癌症生物学与医学（英文版）,2025,22(5):525-538,14.

基金项目

This study was funded by the National Natural Science Foundation of China(No.82273704),Noncommunicable Chronic Diseases-National Science and Technology Major Project(No.2023ZD0501400-2023ZD0501402),Beijing Hospitals Authority's Ascent Plan(DFL20241102),Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support(No.ZLRK202325),China Postdoctoral Science Foundation(2024M760152),Peking University Medicine Fund for World's Leading Discipline or Discipline Cluster Development(No.BMU2022XKQ004),and Science Foundation of Peking University Cancer Hospital(Nos.BJCH2024BJ02,XKFZ2410,BJCH2025CZ04,and 2022-27). （No.82273704）

癌症生物学与医学（英文版）

ISSN：2095-3941

访问量1

下载量0

段落导航